• Veritas has added new clinical information related to pharmacogenomics, metabolic disease and inherited cardiovascular disease to myGenome, the most comprehensive genetic prevention screening analysis for healthy individuals.
• With this update, Veritas further expands its “Genome as a Service” model, based on offering its users valuable information for their health and well-being throughout their lives.
• A pioneer in bringing a high-quality whole genome sequencing and interpretation service, Veritas Intercontinental offers GenomeLife, a subscription service designed to provide continued advancements in genomic science.

Veritas Intercontinental further expands its sequencing and clinical interpretation service of the complete genome, incorporating new genes into the study, mainly related to cardiovascular disease, pharmacogenetics, and adult-onset diabetes.

With this expansion, in addition to updating the available clinical information associated with the genome, Veritas takes a further step in its “Genome as a Service” model, based on offering its users valuable information for their health and well-being throughout life. This is possible because the interpretation of a person’s genomic information is continually expanding through scientific and clinical advances in the field of genomics.

The service expansion allows the myGenome analysis to now include the study of 576 genes. For example, the pharmacogenomics section now includes the study of the CYP2D6 gene very important because it metabolizes 25% of commonly used pharmaceuticals. In the clinical area, genes have been incorporated to cover the recommendations recently published by the American College of Medical Genetics and Genomics. These genes are related to diabetes type MODY, a type of diabetes that appears in age and genes included in the recommendations for the diagnosis of hereditary cardiovascular disease by the American Heart Association.

“Hereditary heart diseases – comments Dr. Luis Izquierdo, Chief Medical Officer of Veritas Intercontinental – are a group of diseases characterized by high clinical and genetic heterogeneity. All of them have in common their association with a higher risk of sudden death, often as the only manifestation of the disease. Genetic services such as myGenome – continues Dr. Izquierdo – provides us with key information to propose the most precise follow-up or treatment of patients and their families”.

Genome Life

A pioneer in the development of high quality whole genome sequencing and interpretation, Veritas Intercontinental offers GenomeLife, a subscription service designed to provide on-going clinical benefits from the myGenome service long after the initial analysis. The service allows patients to receive updates based on the latest advancements in genetics. One example is the Veritas COVID-19 test, which uses existing genomic information to identify genetic factors associated with severe complications in the event of a possible SARS-CoV2 infection.

myGenome: the most comprehensive preventive genetic risk screening analysis available

 “Since its creation, the main objective of Veritas is to universalize the sequencing and interpretation of the genome. To achieve this we have made significant efforts, reducing the cost to offer a more accessible service, but maintaining the highest quality and scientific and technical standards. “ – explains Javier de Echevarría, CEO of Veritas Intercontinental.

myGenome includes information on more than 650 diseases of genetic origin, selected for their prevention related actionability for the individual. It also offers information on more than 225 diseases that can be transmitted children and information on 15 multifactorial diseases, whose development depends on genetics and the environment. Further adding to the depth of the analysis, a pharmacogenomic profile, which allows knowing the reaction of each person to more than 150 drugs, and information on more than 50 genetic traits related to diet, athletics, longevity, nutrition, or metabolism.

The service includes a pre and post test genetic counseling consultation, in the post test consultation the results are delivered, explaining the scope of the information and the appropriate recommendations to personalize medical care based on the results.

About Veritas

Veritas Intercontinental was born in 2018 by Dr. Luis Izquierdo, Dr. Vincenzo Cirigliano and Javier de Echevarría, who accumulate extensive experience in the field of genetics, diagnostics and biotechnology. Initially linked to Veritas Genetics, a company founded in 2014 by Prof. George Church, one of the pioneers in preventive medicine, Veritas was born with the aim of making genome sequencing and its clinical interpretation available to all citizens as a tool to prevent diseases and improve health and quality of life.

Since its inception, Veritas Intercontinental has led the activity and development of the Veritas market in Europe, Latin America, the Middle East and Japan; with the aim of turning genomics into a daily instrument at the service of people’s well-being.